Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 83 (3), 278-86

Defining the Clinical Course of Multiple Sclerosis: The 2013 Revisions

Affiliations

Defining the Clinical Course of Multiple Sclerosis: The 2013 Revisions

Fred D Lublin et al. Neurology.

Abstract

Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment of clinical trials, and treatment decision-making. Standardized descriptions published in 1996 based on a survey of international MS experts provided purely clinical phenotypes based on data and consensus at that time, but imaging and biological correlates were lacking. Increased understanding of MS and its pathology, coupled with general concern that the original descriptors may not adequately reflect more recently identified clinical aspects of the disease, prompted a re-examination of MS disease phenotypes by the International Advisory Committee on Clinical Trials of MS. While imaging and biological markers that might provide objective criteria for separating clinical phenotypes are lacking, we propose refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression. Strategies for future research to better define phenotypes are also outlined.

Figures

Figure 1
Figure 1. The 1996 vs 2013 multiple sclerosis phenotype descriptions for relapsing disease
*Activity determined by clinical relapses and/or MRI activity (contrast-enhancing lesions; new or unequivocally enlarging T2 lesions assessed at least annually); if assessments are not available, activity is “indeterminate.” **CIS, if subsequently clinically active and fulfilling current multiple sclerosis (MS) diagnostic criteria, becomes relapsing-remitting MS (RRMS).
Figure 2
Figure 2. The 1996 vs 2013 multiple sclerosis phenotype descriptions for progressive disease
*Activity determined by clinical relapses assessed at least annually and/or MRI activity (contrast-enhancing lesions; new and unequivocally enlarging T2 lesions). **Progression measured by clinical evaluation, assessed at least annually. If assessments are not available, activity and progression are “indeterminate.” MS = multiple sclerosis; PP = primary progressive; PR = progressive relapsing; SP = secondary progressive.

Comment in

Similar articles

See all similar articles

Cited by 338 PubMed Central articles

See all "Cited by" articles

References

    1. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907–911 - PubMed
    1. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292–302 - PMC - PubMed
    1. Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 2005;4:281–288 - PubMed
    1. Tintore M, Rovira A, Martinez MJ, et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol 2000;21:702–706 - PubMed
    1. O'Riordan JI, Thompson AJ, Kingsley DP, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS: a 10-year follow-up. Brain 1998;121:495–503 - PubMed

Publication types

MeSH terms

Feedback